Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6)

Njira L. Lugogo; Praveen Akuthota; Kaharu Sumino; Sameer K. Mathur; Autumn F. Burnette; Andrew W. Lindsley; Jean Pierre Llanos; Claudio Marchese; Christopher S. Ambrose; Benjamin Emmanuel

doi:10.1007/s12325-025-03316-2

Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6)

Njira L. Lugogo
, Praveen Akuthota
, Kaharu Sumino
, Sameer K. Mathur
, Autumn F. Burnette
, Andrew W. Lindsley
, Jean Pierre Llanos
, Claudio Marchese
, Christopher S. Ambrose
, Benjamin Emmanuel

Research output: Contribution to journal › Comment/debate

Abstract

In the original published version, the sentence “The mean (SD) change from baseline to week 52 in BEC was − 140 (300) cells/μL and in total IgE level was − 81.65 (274.89) IU/mL” should have read as “The mean (SD) change from baseline to week 52 in BEC was − 142 (300) cells/μL and in total IgE level was − 81.65 (274.89) IU/mL”. The original article has been corrected.

Original language	English
Pages (from-to)	4724-4725
Number of pages	2
Journal	Advances in Therapy
Volume	42
Issue number	9
DOIs	https://doi.org/10.1007/s12325-025-03316-2
State	Published - Sep 2025

Access to Document

10.1007/s12325-025-03316-2

Fingerprint

Dive into the research topics of 'Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6)'. Together they form a unique fingerprint.

Cite this

Lugogo, N. L., Akuthota, P., Sumino, K., Mathur, S. K., Burnette, A. F., Lindsley, A. W., Llanos, J. P., Marchese, C., Ambrose, C. S., & Emmanuel, B. (2025). Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6). Advances in Therapy, 42(9), 4724-4725. https://doi.org/10.1007/s12325-025-03316-2

@article{97af5919c0a540a7b883d1c9f97dc66f,

title = "Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6)",

abstract = "In the original published version, the sentence “The mean (SD) change from baseline to week 52 in BEC was − 140 (300) cells/μL and in total IgE level was − 81.65 (274.89) IU/mL” should have read as “The mean (SD) change from baseline to week 52 in BEC was − 142 (300) cells/μL and in total IgE level was − 81.65 (274.89) IU/mL”. The original article has been corrected.",

author = "Lugogo, \{Njira L.\} and Praveen Akuthota and Kaharu Sumino and Mathur, \{Sameer K.\} and Burnette, \{Autumn F.\} and Lindsley, \{Andrew W.\} and Llanos, \{Jean Pierre\} and Claudio Marchese and Ambrose, \{Christopher S.\} and Benjamin Emmanuel",

note = "Publisher Copyright: {\textcopyright} Springer Healthcare Ltd., part of Springer Nature 2025.",

year = "2025",

month = sep,

doi = "10.1007/s12325-025-03316-2",

language = "English",

volume = "42",

pages = "4724--4725",

journal = "Advances in Therapy",

issn = "0741-238X",

number = "9",

}

Lugogo, NL, Akuthota, P, Sumino, K, Mathur, SK, Burnette, AF, Lindsley, AW, Llanos, JP, Marchese, C, Ambrose, CS & Emmanuel, B 2025, 'Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6)', Advances in Therapy, vol. 42, no. 9, pp. 4724-4725. https://doi.org/10.1007/s12325-025-03316-2

Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6). / Lugogo, Njira L.; Akuthota, Praveen; Sumino, Kaharu et al.
In: Advances in Therapy, Vol. 42, No. 9, 09.2025, p. 4724-4725.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6)

AU - Lugogo, Njira L.

AU - Akuthota, Praveen

AU - Sumino, Kaharu

AU - Mathur, Sameer K.

AU - Burnette, Autumn F.

AU - Lindsley, Andrew W.

AU - Llanos, Jean Pierre

AU - Marchese, Claudio

AU - Ambrose, Christopher S.

AU - Emmanuel, Benjamin

PY - 2025/9

Y1 - 2025/9

N2 - In the original published version, the sentence “The mean (SD) change from baseline to week 52 in BEC was − 140 (300) cells/μL and in total IgE level was − 81.65 (274.89) IU/mL” should have read as “The mean (SD) change from baseline to week 52 in BEC was − 142 (300) cells/μL and in total IgE level was − 81.65 (274.89) IU/mL”. The original article has been corrected.

AB - In the original published version, the sentence “The mean (SD) change from baseline to week 52 in BEC was − 140 (300) cells/μL and in total IgE level was − 81.65 (274.89) IU/mL” should have read as “The mean (SD) change from baseline to week 52 in BEC was − 142 (300) cells/μL and in total IgE level was − 81.65 (274.89) IU/mL”. The original article has been corrected.

UR - https://www.scopus.com/pages/publications/105013575846

U2 - 10.1007/s12325-025-03316-2

DO - 10.1007/s12325-025-03316-2

M3 - Comment/debate

C2 - 40699278

AN - SCOPUS:105013575846

SN - 0741-238X

VL - 42

SP - 4724

EP - 4725

JO - Advances in Therapy

JF - Advances in Therapy

IS - 9

ER -

Lugogo NL, Akuthota P, Sumino K, Mathur SK, Burnette AF, Lindsley AW et al. Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6). Advances in Therapy. 2025 Sep;42(9):4724-4725. doi: 10.1007/s12325-025-03316-2

Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study (Advances in Therapy, (2025), 42, 7, (3334-3353), 10.1007/s12325-025-03231-6)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this